Promontory Therapeutics Inc., a New York-based clinical stage pharmaceutical company, announced on Monday that it has named Stanley J Musial, CPA, MBA, as its new chief financial officer.
Musial has more than 25 years of financial, strategic and managerial experience with public and private biotechnology companies. He has earlier served as CFO of Aruvant Sciences, CFO and chief business officer of Xenikos BV, CFO of Erydel SpA, executive vice president and CFO at Egalet, CFO and financial positions at several other biotechnology, medical device and healthcare services companies. He started his career at the public accounting firm KPMG.
Musial has an MBA degree from Temple University, a BS degree in Accounting from Pennsylvania State University, and is a certified public accountant.
Talamo to Chair CXL Ophthalmics Board of Directors
NeuroBo Pharmaceuticals names interim chief executive officer and president
Sensorium Therapeutics names new chief scientific officer
Borgman Named to NiKang Therapeutics Board of Directors
Dobmeier, Waldstreicher Named to Structure Therapeutics Board of Directors